• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Keane John M

    6/11/25 4:34:21 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SIGA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    KEANE JOHN M

    (Last) (First) (Middle)
    C/O SIGA TECHNOLOGIES, INC.
    31 EAST 62ND STREET

    (Street)
    NEW YORK NY 10065

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    SIGA TECHNOLOGIES INC [ SIGA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/10/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 06/10/2025 A 24,116 (2) (2) Common Stock, par value $.0001 per share 24,116 $0 24,116 D
    Explanation of Responses:
    1. Restricted stock units ("RSUs") represent contingent rights to receive common stock of the Company on a one-for-one basis, of which up to 7,235 RSUs are expected to settle in cash value thereof but may be settled in shares at the discretion of the board of directors.
    2. The RSUs fully vest on the date of the Company's 2026 annual meeting of stockholders.
    /s/ Kevin Buckley, as Attorney-in-Fact 06/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SIGA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SIGA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SIGA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

    NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Generated Product Revenues of $79 million for the Three Months Ended June 30Awarded Additional Development Funding of $27 million under the BARDA 19C Contract during the Three Months Ended June 30Corporate Update Conference Call Today at 4:30 PM ET SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2025. "In the second quarter, we achieved two positive milestones: significant product revenues and expanded development funding under the BARDA 19C contract," stated Diem Nguyen, Chief Executive Officer. "Specifically, in the second qu

    8/5/25 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

    NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-173

    7/29/25 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Reports Financial Results for Three Months Ended March 31, 2025

    Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March$94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2025. "SIGA has carried its momentum from 2024 into 2025, achieving steady progress on its key initiatives," stated Diem Nguyen, Chief Executive Officer. "In the first quarter, an international sale of approximately $6 million marks what we expe

    5/8/25 4:05:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive VP & CFO Luckshire Daniel J converted options into 24,193 shares and covered exercise/tax liability with 12,346 shares, increasing direct ownership by 5% to 275,064 units (SEC Form 4)

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    7/2/25 9:03:24 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Scientific Officer Hruby Dennis E converted options into 32,258 shares and covered exercise/tax liability with 10,467 shares, increasing direct ownership by 13% to 191,047 units (SEC Form 4)

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    7/2/25 8:58:34 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Keane John M

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    6/11/25 4:34:21 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    SEC Filings

    View All

    SEC Form 10-Q filed by SIGA Technologies Inc.

    10-Q - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    8/5/25 4:53:57 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    8/5/25 4:06:53 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    6/12/25 4:18:33 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Financials

    Live finance-specific insights

    View All

    SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

    NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Generated Product Revenues of $79 million for the Three Months Ended June 30Awarded Additional Development Funding of $27 million under the BARDA 19C Contract during the Three Months Ended June 30Corporate Update Conference Call Today at 4:30 PM ET SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2025. "In the second quarter, we achieved two positive milestones: significant product revenues and expanded development funding under the BARDA 19C contract," stated Diem Nguyen, Chief Executive Officer. "Specifically, in the second qu

    8/5/25 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

    NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-173

    7/29/25 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Reports Financial Results for Three Months Ended March 31, 2025

    Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March$94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2025. "SIGA has carried its momentum from 2024 into 2025, achieving steady progress on its key initiatives," stated Diem Nguyen, Chief Executive Officer. "In the first quarter, an international sale of approximately $6 million marks what we expe

    5/8/25 4:05:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Leadership Updates

    Live Leadership Updates

    View All

    SIGA Appoints Retired General John M. Keane to its Board of Directors

    NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army General John "Jack" Keane to its Board of Directors, effective immediately. General Keane, a retired four-star general, completed 37 years of public service in December 2003, culminating with his appointment as acting Chief of Staff and Vice Chief of Staff of the U.S. Army from 1999 to 2003. He is a foreign policy and national security expert who serves as an advisor to presidents, cabinet officials, members of congress, international leaders, CEOs, and business leaders. He also provide

    3/18/25 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Names Larry Miller General Counsel

    NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today. "With over twenty years of experience in the biopharmaceutical industry, Larry brings a proven track record of growing commercial businesses, successful mergers and acquisitions, and strong corporate governance, which are critical to driving SIGA's continued success and growth strategies forward," said Diem Nguyen, Chief Executive Officer.  "Larry will be instrumental in helping us expand our reach on a global scale and maximize the ben

    3/25/24 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

    NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company's Board of Directors. SIGA's current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024. "The appointment of Diem Nguyen as our new CEO marks a significant milestone for SIGA as we continue to expand our partnerships with governments across the world in global health security initiatives and medical countermeasure preparedness," said Josep

    1/22/24 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SIGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SIGA Technologies Inc.

    SC 13G - SIGA TECHNOLOGIES INC (0001010086) (Subject)

    2/1/24 3:54:12 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by SIGA Technologies Inc. (Amendment)

    SC 13G/A - SIGA TECHNOLOGIES INC (0001010086) (Subject)

    2/14/23 4:42:47 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SIGA Technologies Inc.

    SC 13G - SIGA TECHNOLOGIES INC (0001010086) (Subject)

    6/24/22 4:05:38 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care